LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Clinical trials for LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL explained in plain language.
Never miss a new study
Get alerted when new LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL trials appear
Sign up with your email to follow new studies for LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise for Hard-to-Treat leukemia and lymphoma
Disease control CompletedThis phase 2 study tested an oral drug called pirtobrutinib in 87 Chinese adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma who had already received standard treatments. The goal was to see how well the drug shrank tumors and to check f…
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New cocktail aims to tackle tough leukemia
Disease control CompletedThis phase II study tested a combination of three drugs—ibrutinib, fludarabine, and pembrolizumab—in 15 people with high-risk or relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal was to see if the combo could produce a complete r…
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Chemo-Free combo shows promise for CLL patients
Disease control CompletedThis phase 2 trial tested a chemotherapy-free combination of two drugs, obinutuzumab and ibrutinib, in 135 people with previously untreated chronic lymphocytic leukemia (CLL). The treatment was given for nine months, and then the next steps were decided based on how much leukemia…
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New antibody drug shows promise in early blood cancer trial
Disease control CompletedThis early-stage trial tested a new drug called JNJ-75348780 in 147 people with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals were to check safe…
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC